Navepegritide

那韦培肽

Report date: 2026/04/09 20:00:21

Base Information

Drug NameNavepegritide
Drug Alias NameTransCon C-type natriuretic peptideC型利尿钠肽前药TransCon CNPC-type natriuretic peptide prodrugYUVIWEL +[6] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionC-type natriuretic peptide replacements
TargetsC-type natriuretic peptide
Therapy Area/IndicationsAchondroplasia
Global Approved IndicationsAchondroplasia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2026/02/27
Country/TerritoryCanadaUnited StatesSweden +[17] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAscendis Pharma
China Registration ClassN/A

Develop Information

Active CompaniesVisen Pharmaceuticals (Shanghai) Co LtdAscendis Pharma Growth Disorders AsAscendis Pharma A/S +[4] 
Inactive CompaniesN/A
Active IndicationsAchondroplasia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A